» Articles » PMID: 26788248

Protective Effects of D-Penicillamine on Catecholamine-Induced Myocardial Injury

Overview
Publisher Wiley
Date 2016 Jan 21
PMID 26788248
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Iron and copper release participates in the myocardial injury under ischemic conditions and hence protection might be achieved by iron chelators. Data on copper chelation are, however, sparse. The effect of the clinically used copper chelator D-penicillamine in the catecholamine model of acute myocardial injury was tested in cardiomyoblast cell line H9c2 and in Wistar Han rats. D-Penicillamine had a protective effect against catecholamine-induced injury both in vitro and in vivo. It protected H9c2 cells against the catecholamine-induced viability loss in a dose-dependent manner. In animals, both intravenous D-penicillamine doses of 11 (low) and 44 mg/kg (high) decreased the mortality caused by s.c. isoprenaline (100 mg/kg) from 36% to 14% and 22%, respectively. However, whereas the low D-penicillamine dose decreased the release of cardiac troponin T (specific marker of myocardial injury), the high dose resulted in an increase. Interestingly, the high dose led to a marked elevation in plasma vitamin C. This might be related to potentiation of oxidative stress, as suggested by additional in vitro experiments with D-penicillamine (iron reduction and the Fenton reaction). In conclusion, D-penicillamine has protective potential against catecholamine-induced cardiotoxicity; however the optimal dose selection seems to be crucial for further application.

Citing Articles

Dexmedetomidine enables copper homeostasis in cerebral ischemia/reperfusion via ferredoxin 1.

Guo Q, Ma M, Yu H, Han Y, Zhang D Ann Med. 2023; 55(1):2209735.

PMID: 37162502 PMC: 10173798. DOI: 10.1080/07853890.2023.2209735.


Comprehensive review of cardiovascular toxicity of drugs and related agents.

Mladenka P, Applova L, Patocka J, Costa V, Remiao F, Pourova J Med Res Rev. 2018; 38(4):1332-1403.

PMID: 29315692 PMC: 6033155. DOI: 10.1002/med.21476.

References
1.
Mladenka P, Macakova K, Zatloukalova L, Rehakova Z, Singh B, Prasad A . In vitro interactions of coumarins with iron. Biochimie. 2010; 92(9):1108-14. DOI: 10.1016/j.biochi.2010.03.025. View

2.
Ibanez B, Heusch G, Ovize M, Van de Werf F . Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol. 2015; 65(14):1454-71. DOI: 10.1016/j.jacc.2015.02.032. View

3.
Brewer G . Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases. Metallomics. 2011; 1(3):199-206. DOI: 10.1039/b901614g. View

4.
Gromadzka G, Grazyna G, Karpinska A, Agata K, Przybylkowski A, Adam P . Treatment with D-penicillamine or zinc sulphate affects copper metabolism and improves but not normalizes antioxidant capacity parameters in Wilson disease. Biometals. 2013; 27(1):207-15. PMC: 3905172. DOI: 10.1007/s10534-013-9694-3. View

5.
Grammer T, Kleber M, Silbernagel G, Pilz S, Scharnagl H, Lerchbaum E . Copper, ceruloplasmin, and long-term cardiovascular and total mortality (the Ludwigshafen Risk and Cardiovascular Health Study). Free Radic Res. 2014; 48(6):706-15. DOI: 10.3109/10715762.2014.901510. View